Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
173 Prostate Cancer Trials near Houston, TX
Power is an online platform that helps thousands of Prostate Cancer patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerApalutamide + Hormone Therapy for Prostate Cancer
Houston, Texas
This trial tests whether combining apalutamide with another treatment helps men with high-risk prostate cancer undergoing radiation therapy. The treatment aims to block and reduce male hormones that fuel cancer growth, potentially preventing the cancer from spreading. Apalutamide has been developed for treating prostate cancer and has shown effectiveness.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Sex:Male
Key Eligibility Criteria
Disqualifiers:Metastasis, Seizure History, Others
Must Be Taking:GnRH Agonists
1503 Participants Needed
Apalutamide + ADT for Prostate Cancer
Houston, Texas
The purpose of this study is to determine if the addition of apalutamide to ADT provides superior efficacy in improving radiographic progression-free survival (rPFS) or overall survival (OS) for participants with mHSPC.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Sex:Male
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Visceral Metastases, Others
Must Be Taking:ADT
1052 Participants Needed
Enzalutamide + Leuprolide for Prostate Cancer
Houston, Texas
The purpose of this study is to assess enzalutamide plus leuprolide in patients with high-risk nonmetastatic prostate cancer progressing after radical prostatectomy or radiotherapy or both.
The randomized / blinded portion of the study is now completed following primary endpoint analyses. The study remains ongoing in open label format.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Sex:Male
Key Eligibility Criteria
Disqualifiers:Metastatic Disease, Recent Surgery, Others
Must Not Be Taking:Hormonal Therapy, Chemotherapy
1068 Participants Needed
This trial tests apalutamide added to a standard treatment for advanced prostate cancer. It targets patients whose cancer has spread and who haven't had chemotherapy. The treatment works by blocking and lowering male hormones that help cancer grow. Apalutamide has shown efficacy in treating different stages of prostate cancer.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Sex:Male
Key Eligibility Criteria
Disqualifiers:Small Cell Carcinoma, Brain Metastases, Others
Must Be Taking:Androgen Deprivation Therapy
982 Participants Needed
Apalutamide for Castration-Resistant Prostate Cancer
Houston, Texas
The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Sex:Male
Key Eligibility Criteria
Disqualifiers:Metastases, Seizure History, Uncontrolled Hypertension, Others
Must Be Taking:Androgen Deprivation Therapy
1207 Participants Needed
TAK-700 vs. Bicalutamide for Prostate Cancer
Houston, Texas
The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Sex:Male
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Cardiac Disease, Hypertension, HIV, Others
Must Be Taking:LHRH Agonists
1313 Participants Needed
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as steroid 17alpha-monooxygenase TAK-700, when used with other hormone therapy, may lessen the amount of androgens made by the body. Radiation therapy uses high energy x rays to kill tumor cells. This may be an effective treatment for prostate cancer when combined with hormone therapy. Studying quality-of-life in patients having cancer treatment may help identify the intermediate- and long-term effects of treatment on patients with prostate cancer.
PURPOSE: This randomized phase III trial is studying the use of hormone therapy, including TAK-700, together with radiation therapy in treating patients with prostate cancer.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Sex:Male
Key Eligibility Criteria
Disqualifiers:Metastatic Disease, Heart Failure, Others
Must Be Taking:Hormone Therapy
239 Participants Needed
ProstAtak® Immunotherapy + Radiation for Prostate Cancer
Houston, Texas
This trial is testing ProstAtak® immunotherapy with radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAtak® kills cancer cells and helps the immune system learn to attack any remaining cancer cells, potentially improving treatment outcomes.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Sex:Male
Key Eligibility Criteria
Disqualifiers:Not Listed
711 Participants Needed
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells.
PURPOSE: This randomized phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Sex:Male
Key Eligibility Criteria
Disqualifiers:Bladder Cancer, AIDS, Others
Must Not Be Taking:LHRH Agonists, Anti-androgens
2592 Participants Needed
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Androgens can cause the growth of prostate cancer cells. Androgen-deprivation therapy may lessen the amount of androgens made by the body. It is not yet known whether radiation therapy is more effective with or without androgen-deprivation therapy in treating patients with prostate cancer.
PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared with radiation therapy given together with androgen-deprivation therapy in treating patients with prostate cancer.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Sex:Male
Key Eligibility Criteria
Disqualifiers:Gleason Score ≥ 8, PSA > 20, Prior Malignancy, Others
Must Not Be Taking:LHRH Agonists, Antiandrogens, Estrogens, Others
1538 Participants Needed
This study is evaluating whether radiation therapy is more effective than short-term androgen deprivation therapy for prostate cancer.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Sex:Male
Key Eligibility Criteria
Disqualifiers:Metastases, Invasive Malignancy, Others
Must Not Be Taking:Finasteride, Dutasteride, Chemotherapy, Others
1792 Participants Needed
PF-06821497 + Enzalutamide for Prostate Cancer
Houston, Texas
Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment.
The primary objective of this clinical trial is to assess the radiographic progression free survival (rPFS) of the combination of PF-06821497 plus enzalutamide versus physician's choice of enzalutamide or docetaxel.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Sex:Male
Key Eligibility Criteria
Disqualifiers:Cardiovascular Disease, Brain Metastasis, Others
Must Not Be Taking:Chemotherapy, ARSi, PARP, Others
600 Participants Needed
Opevesostat + Hormone Therapy for Prostate Cancer
Houston, Texas
This trial is testing a new drug called opevesostat for advanced prostate cancer patients who don't respond to usual care. The drug aims to stop the cancer from growing and spreading, potentially helping patients live longer.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Gastrointestinal Condition, Diabetes, Cardio/cerebro-vascular, Others
Must Be Taking:Hormone Replacement Therapy
1314 Participants Needed
Long-Term Safety of AAA617 for Prostate Cancer
Houston, Texas
The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other AAA617 causally related serious adverse event(s) in the long-term in adults with prostate cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis sponsored clinical trials.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Sex:Male
Key Eligibility Criteria
Disqualifiers:Inability To Complete Examinations
700 Participants Needed
Androgen Ablation + Niraparib for Prostate Cancer
Houston, Texas
This phase II trial studies the effect of androgen ablation therapy with or without niraparib after standard of care radiation therapy in treating patients with prostate cancer that has not spread to other parts of the body (localized) or that has spread to nearby tissue or lymph nodes (locally advanced). Androgen ablation therapy (also known as hormone therapy) lowers the levels of male hormones called androgens in the body. Androgens stimulate prostate cancer cells to grow. There are 2 types of androgen ablation therapy given in this study: AAP + ADT and Apa + ADT. AAP + ADT is the treatment combination of the drugs abiraterone acetate and prednisone (AAP) given with androgen deprivation therapy (ADT, also known as androgen deprivation therapy or androgen suppression medication, which is used as standard of care to lower testosterone levels in men with high risk localized or metastatic prostate cancer). Apa + ADT is the treatment combination of the drug apalutamide (Apa) given with ADT. Androgen ablation therapy with or without niraparib after radiation therapy may help to control the disease in patients with prostate cancer.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Sex:Male
Key Eligibility Criteria
Disqualifiers:Metastatic Disease, MDS/AML, Others
Must Be Taking:Androgen Ablation Therapy
200 Participants Needed
This phase II trial studies the effect of cabazitaxel, carboplatin, and cetrelimab followed by niraparib with or without cetrelimab in treating patients with aggressive variant prostate cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as cabazitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as niraparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Immunotherapy with monoclonal antibodies, such as cetrelimab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving niraparib with or without cetrelimab, after treatment with cabazitaxel, carboplatin, and cetrelimab, may help control aggressive variant prostate cancer.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Sex:Male
Key Eligibility Criteria
Disqualifiers:MDS/AML, Uncontrolled Infection, Autoimmune Disorders, Others
Must Not Be Taking:Immunosuppressants, Anti-PD1, Anti-PDL1
120 Participants Needed
Lutetium-177-PSMA-617 for Prostate Cancer
Houston, Texas
The purpose of this study is to evaluate the safety and tolerability of Lutetium-177-PSMA-617 (PLUVICTO) in patients with metastatic castration-resistant prostate cancer (mCRPC) and extensive bone metastases, which appear as a "super scan" pattern on a bone scan.
Pluvicto is FDA-approved, but patients with super scan bone scans were previously excluded from the VISION clinical trial, leaving a knowledge gap.
The study will enroll up to 30 men with metastatic castration-resistant prostate cancer, with an initial dosing approach that differs from the standard dose.
The safety and tolerability of PLUVICTO will be evaluated in this study, with a focus on identifying the optimal dose for this population.
This study addresses an important gap in understanding how Pluvicto performs in mCRPC patients with super scan findings.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Sex:Male
Key Eligibility Criteria
Disqualifiers:Renal Impairment, CNS Metastases, Others
Must Be Taking:Androgen Receptor-axis-targeted Therapy
30 Participants Needed
The purpose of this Phase 1/2 study is to test the overall safety, tolerability, and effectiveness of the combination investigational drugs evofosfamide, zalifrelimab, and balstilimab in treating advanced or metastatic castration-resistant prostate cancer, pancreatic cancer, and human papilloma virus (HPV)-negative squamous cell carcinoma of the head and neck (SCCHN).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Autoimmune Diseases, Uncontrolled Infection, Others
Must Be Taking:Anti-androgens
71 Participants Needed
INV-9956 for Prostate Cancer
Houston, Texas
This is a Phase 1 and Phase 2 study to determine the safety profile, RDR and/or MTD, DLT, PK/PD, and preliminary antitumor activity of INV-9956 in adult patients with advanced mCRPC.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Sex:Male
Key Eligibility Criteria
Disqualifiers:Crohn's, Diabetes, Cardiac Disease, Others
Must Be Taking:GnRH Analogue
84 Participants Needed
FPI-2265 for Metastatic Prostate Cancer
Houston, Texas
This is an open-label, randomized, multicenter study of FPI-2265 (225Ac-PSMA-I\&T). Patient population is adult participants with PSMA positive mCRPC who have had previous treatment with with 177Lu-PSMA-617 or another 177Lu-PSMA radioconjugate (RC). The purpose of the study is to determine the safety and tolerability, and recommended dose and regiment of FPI-2265.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Sex:Male
Key Eligibility Criteria
Disqualifiers:CNS Metastases, Liver Metastases, Others
Must Be Taking:Androgen-deprivation Therapy
100 Participants Needed
Why Other Patients Applied
"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."
ID
Pancreatic Cancer PatientAge: 40
"I've tried chemotherapy and radiation but the cancer recurred. My oncologist suggested that I might want to try a clinical trial given my situation. Just starting to research, hoping to learn more."
FR
Lung Cancer PatientAge: 71
"I had two chemotherapy regímens without success, three surgeries during which the tumor could not be resected. These clinical trials are a light of hope for me and my family (I have a five year old child) and I have read about cases of success in other types of cancer with this treatment. I think that I am a perfect candidate for this tríal. Thank you."
UM
Pancreatic Cancer PatientAge: 48
"I've had radiation and as far as I know I’m in remission, but my brother passed away with the same condition. I don’t mind helping research for a cure... my husband passed away with pancreatic cancer. I've had a stepdaughter that passed away with ovarian cancer at 20. I just think it’s time to knock cancer out! I'd really like to help find better treatments by participating in a trial."
EQ
Lung Cancer PatientAge: 70
"My mom has cholangiocarcinoma with bone mts (FGFR2 mutation). She really needs this trial to survive. She’s active and her analysis is ok, but we have very limited other options. Hope to work with a high-quality clinic to prolong her quality and duration of life."
OF
Cholangiocarcinoma PatientAge: 54
ADI-PEG 20 + Chemotherapy for Prostate Cancer
Houston, Texas
To find the best dose of ADI-PEG20 that can be given in combination with carboplatin and cabazitaxel to patients with AVPC.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Sex:Male
Key Eligibility Criteria
Disqualifiers:Uncontrolled Infection, Viral Hepatitis, Lung Disease, Others
Must Not Be Taking:Carboplatin, Cisplatin, Cabazitaxel
30 Participants Needed
To learn if the proposed dose of 177Lu rhPSMA-10.1 is safe. Phase 2 will open if the Phase 1 dose is found to be safe.
To learn about the safety and effects of 177Lu rhPSMA-10.1 alone and with androgen deprivation therapy (ADT) on patients with high-risk, localized prostate cancer before they have surgery to remove the disease.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Cardiovascular Disease, Other Malignancy, Others
Must Not Be Taking:Tenofovir, Corticosteroids, Others
36 Participants Needed
Talazoparib + Enzalutamide for Prostate Cancer
Houston, Texas
To learn about the effectiveness of adding talazoparib to the standard of care treatment combination of androgen ablation therapy (hormone therapy, also known as ADT) and enzalutamide in patients with prostate cancer that has spread into the lymph nodes.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Sex:Male
Key Eligibility Criteria
Disqualifiers:Small Cell Histology, Bone Metastasis, Chemotherapy, Seizures, Hypertension, Others
Must Be Taking:Androgen Ablation Therapy
30 Participants Needed
AAA617 Alone or Combined With ARPI for Prostate Cancer
Houston, Texas
This trial is testing a new radioactive drug called AAA617, alone or with hormone-blocking medication, in men with a specific type of prostate cancer that hasn't spread and doesn't respond to usual treatments. The drug aims to kill cancer cells with radiation while the hormone blocker stops their growth.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Sex:Male
Key Eligibility Criteria
Disqualifiers:Metastatic Disease, Cardiac Disease, Seizure, Others
Must Be Taking:GnRH Agonists/antagonists
80 Participants Needed
Radioactive Drug Therapy for Prostate Cancer
Houston, Texas
This trial studies how well lutetium Lu 177 dotatate works in treating patients with a specific type of prostate cancer that has spread. The drug targets cancer cells and releases radiation to kill them. Lutetium-177 (Lu-177) PSMA therapy is a targeted treatment for advanced prostate cancer that has shown promising results.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Sex:Male
Key Eligibility Criteria
Disqualifiers:Uncontrolled Hypertension, Stroke, Others
Must Be Taking:LHRH Agonists/antagonists
30 Participants Needed
Focal Cryoablation for Prostate Cancer
Houston, Texas
To learn if using cryotherapy to treat only the part of the prostate known to contain cancer is effective in controlling prostate cancer
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Sex:Male
Key Eligibility Criteria
Disqualifiers:Gleason Grade 4 Or 5, Others
30 Participants Needed
Abbreviated Biparametric MRI for Prostate Cancer
Houston, Texas
This trial is testing a new MRI scan method for men with newly diagnosed prostate cancer. The scan combines detailed imaging and water movement analysis to detect cancer. The goal is to see if this method is as effective as the standard MRI but simpler and cheaper.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Prior Surgery, Radiotherapy, Pacemakers, Others
Must Not Be Taking:Androgen Deprivation Therapy
302 Participants Needed
Genomic Biomarker-Selected Therapy for Prostate Cancer
Houston, Texas
The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response.
Each participant will be treated with 8 weeks of a luteinizing hormone-releasing hormone agonist (LHRHa) plus apalutamide (APA) while genome sequence characterization is being done. Participants with biopsy specimens deemed unevaluable for genomic testing will remain on LHRHa plus APA for an additional 16 weeks.
Participants with evaluable tissue will be assigned to one of the open-label sub-studies on the basis of genomic profiling results. Within each group, they will be randomized to a specific treatment arm either LHRHa plus APA alone or adding abiraterone acetate and prednisone, docetaxel or niraparib.
The study will evaluate the response rate and outcomes after radical prostatectomy in each arm of the trial.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Sex:Male
Key Eligibility Criteria
Disqualifiers:T4 Prostate Cancer, Hypogonadism, HIV, Cardiac Disease, Others
Must Be Taking:LHRHa, Apalutamide
315 Participants Needed
Erdafitinib for Castration-Resistant Prostate Cancer
Houston, Texas
This phase II trial studies the effect of erdafitinib in treating patients with prostate cancer that grows and continues to spread despite the surgical removal of the testes or drugs to block androgen production (castration-resistant). Erdafitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erdafitinib may help control disease in patients with castration-resistant prostate cancer. In addition, studying samples of blood, tissue, plasma, and bone marrow from patients with castration-resistant prostate cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Sex:Male
Key Eligibility Criteria
Disqualifiers:Hypertension, Eye Conditions, Cardiovascular, Others
Must Be Taking:AR-targeting Agents
11 Participants Needed
Chemoimmunotherapy for Prostate Cancer
Houston, Texas
This trial tests a combination of immune-boosting and chemotherapy drugs in men with aggressive prostate cancers. The treatment aims to strengthen the immune system to fight cancer and directly kill cancer cells.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Sex:Male
Key Eligibility Criteria
Disqualifiers:Immunodeficiency, Active Infection, Autoimmune, Others
Must Be Taking:ADT
41 Participants Needed
Know someone looking for new options?
Spread the word